12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revestive regulatory update

NPS and Takeda said the European Commission approved Revestive teduglutide to treat short bowel syndrome (SBS). Takeda plans to initially provide Revestive in Europe through a named patient program....

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >